Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk.
Antibiotic resistance is a potential problem around the world. Among the bacteria that cause community-acquired pneumonia (CAP), resistance in Streptococcus pneumoniae is a primary concern. Resistance can occur through genetic mutations in the bacterial strain itself or can be acquired through use of some antibiotics that have a high resistance potential. In this article, Dr Cunha explores the misperceptions about antibiotic resistance and its occurrence, as well as the most appropriate therapy for CAP in the clinical setting.
Cunha
Burke A
BA
State University of New York School of Medicine at Stony Brook, New York, USA.
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D003937:Diagnosis, Differential; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones; D006801:Humans; D007769:Lactams; D010403:Penicillin Resistance; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects; D018440:beta-Lactam Resistance
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007769:Lactams